With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Key takeaways De Amerikaanse toezichthouder FDA (Food and Drug Administration) heeft Wegovy versneld goedgekeurd voor de ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Wegovy is now positioned as the first and only GLP-1 treatment.

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Madrigal is van plan REZDIFFRA in Europa land voor land te lanceren, te beginnen met Duitsland in het vierde kwartaal van 2025. Het bedrijf schat dat ongeveer 370.000 gediagnosticeerde MASH-patiënten ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Aandelen Novo Nordisk stegen maandag nadat het in de VS goedkeuring kreeg voor het gebruik van het afslankmiddel Wegovy bij de behandeling van een ernstige leveraandoening, positief nieuws voor de far ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...